Which patients with COPD could benefit from Trelegy Ellipta?

Patients with COPD who are symptomatic and at risk of an exacerbation despite dual maintenance therapy may be suitable for Trelegy Ellipta.1

Fictional patient with COPD

For patients with COPD like Sylvia, ICS/LABA may not be enough

Sylvia is on treatment with a dual maintenance therapy, symptomatic and at risk of an exacerbation:

  • Has worsening of symptoms, or
  • Has experienced an exacerbation treated with antibiotics or oral corticosteroid, in the past 12 months

How is COPD impacting her life?

  • Starting to miss social events with friends
  • Struggles to keep her small garden tidy
  • Difficulty walking to the shops
  • Can’t keep up when playing with young grandchildren

It is important to reduce exacerbations. Even a single exacerbation can be associated with poorer outcomes for patients with COPD2-4

Effect on lung function

~37% faster decline in lung function vs. no exacerbation*2

 Risk of heart attack

2x increased risk of myocardial infarction in 1-5 days after exacerbation**3

Risk of death

~50% risk of death within 5 years following a hospitalised exacerbation4

*Post-hoc analysis of the TORCH study (moderate or severe COPD). The primary endpoint of the original study did not reach statistical significance. Analysis includes patients on active treatment and placebo. Percentage represents changes in decline in FEV1 in ml/year. Data shown compares patients with >0-1 moderate /severe exacerbations per annum vs. 0 exacerbations per annum.

**n=25,857. 2.27 fold (95%CI, 1.1-4.7; p=0.03) increased relative risk of MI 1 to 5 days after exacerbation (defined by prescription of both steroids and antibiotics). There were 20,101 exacerbations and 8 MI events in the 1-5 day post exacerbation period, so the odds of an MI were 1 in 2513 exacerbations.

Prescribing Information Links

Trelegy Ellipta Prescribing Information (pdf)

Trelegy Ellipta OD is indicated for maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting β2-agonist or a combination of a long-acting β2-agonist and a long-acting muscarinic antagonist.1


ICS, inhaled corticosteroid; LABA, long-acting β2-agonist; LAMA, long-acting muscarinic antagonist; MI, myocardial infarction; QoL, quality of life


  1. Trelegy SmPC
  2. Celli B et al. Am J Respir Crit Care Med 2008; 178:332-338 (see table 5, p.336)
  3. Donaldson GC et al. Chest 2010; 137:1091-1097
  4. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease (GOLD) 2020 pages 30 and 105.

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App Store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441

October 2022 | PM-GB-FVU-WCNT-200012 (V5.0)